ALIM Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally...

Stats
Today's Volume	7 578.00
Average Volume	73 025.00
Market Cap	190.05M
EPS	$0 ( 2024-03-07 )
Next earnings date	( $-0.0400 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.32
ATR14	$0.0550 (1.54%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-26	Ashman Philip	Sell	12 103	Common Stock
2024-03-11	Werner Jason M.	Buy	1 800	Restricted Stock Units
2024-03-11	Wood Todd Michael	Buy	125 000	Performance-Based Restricted Stock Units
2024-03-11	Wood Todd Michael	Buy	125 000	Restricted Stock Units
2024-03-11	Eiswirth Richard S Jr	Buy	14 700	Restricted Stock Units

INSIDER POWER
27.00
Last 77 transactions
Buy: 33 555 909 \| Sell: 20 075 544

Alimera Sciences Inc Correlation

10 Most Positive Correlations
ADV	0.943
RCMT	0.942
BTWN	0.941
AMZN	0.933
USLM	0.933
KE	0.93
RXST	0.929
HUSN	0.928
MRAM	0.928
ALTO	0.928

10 Most Negative Correlations
AKU	-0.948
IMBI	-0.942
AMRB	-0.936
RMBS	-0.93
STRM	-0.928
AGRI	-0.927
ENNV	-0.924
LOPE	-0.923
EYEN	-0.921
PTMN	-0.919

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Alimera Sciences Inc Financials

Annual	2023
Revenue:	$80.75M
Gross Profit:	$61.17M (75.75 %)
EPS:	$-0.790

Q4	2023
Revenue:	$26.31M
Gross Profit:	$19.64M (74.66 %)
EPS:	$-0.0695

Q3	2023
Revenue:	$23.36M
Gross Profit:	$20.61M (88.20 %)
EPS:	$-0.0422

Q2	2023
Revenue:	$17.54M
Gross Profit:	$15.11M (86.17 %)
EPS:	$-1.240

Financial Reports:

No articles found.

Alimera Sciences Inc

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.